Venture Capital Fundraising in Healthcare Remains Healthy; Silicon Valley Bank Releases 15th Edition of Healthcare Investments and Exits Report
Silicon Valley Bank's latest Healthcare Investments and Exits Report reveals that venture capital investment in healthcare reached $23 billion in 2024, up from $20 billion in 2023. Artificial Intelligence emerged as a dominant force, particularly in biopharma, capturing 30% of total healthcare investment.
The biopharma AI sector experienced remarkable growth, with investments exceeding $5.6 billion in 2024, marking a 300% increase from 2023 and surpassing 2021 figures by nearly $2 billion. Notably, 71% of biopharma AI investments came from mega deals exceeding $100 million.
The report highlights several key trends: seed rounds represented 40% of all deals, with 35% of companies receiving seed funding utilizing AI. Valuations showed a 1.5x median increase for companies raising after down rounds. While healthtech focuses on proven companies, diagnostics/tools sector shows promise in liquid biopsies and precision diagnostics, and the device sector sees potential revival through hospital-focused innovations.
Il Rapporto sugli Investimenti e le Uscite Sanitarie dell'ultima edizione di Silicon Valley Bank rivela che gli investimenti in capitale di rischio nel settore sanitario hanno raggiunto $23 miliardi nel 2024, in aumento rispetto ai $20 miliardi del 2023. L'Intelligenza Artificiale è emersa come una forza dominante, in particolare nel biopharma, catturando il 30% dell'investimento totale nel settore sanitario.
Il settore dell'AI biopharma ha registrato una crescita straordinaria, con investimenti superiori a $5.6 miliardi nel 2024, segnando un aumento del 300% rispetto al 2023 e superando i valori del 2021 di quasi $2 miliardi. È interessante notare che il 71% degli investimenti in AI biopharma proviene da mega affari superiori ai $100 milioni.
Il rapporto evidenzia alcune tendenze chiave: i round di seed rappresentavano il 40% di tutti gli affari, con il 35% delle aziende che ricevevano finanziamenti seed che utilizzavano AI. Le valutazioni hanno mostrato un aumento mediano di 1.5x per le aziende che raccolgono dopo i round di discesa. Mentre il settore healthtech si concentra su aziende consolidate, il settore diagnostico/strumenti mostra promesse nelle biopsie liquide e nella diagnostica di precisione, e il settore dei dispositivi vede potenziali riprese grazie a innovazioni focalizzate sugli ospedali.
El Informe de Inversiones y Salidas en Salud de Silicon Valley Bank revela que la inversión de capital de riesgo en el sector salud alcanzó $23 mil millones en 2024, aumentando desde los $20 mil millones en 2023. La Inteligencia Artificial emergió como una fuerza dominante, especialmente en biopharma, capturando el 30% de la inversión total en el sector salud.
El sector de AI biopharma experimentó un crecimiento notable, con inversiones que superaron los $5.6 mil millones en 2024, marcando un incremento del 300% respecto a 2023 y superando las cifras de 2021 por casi $2 mil millones. Cabe destacar que el 71% de las inversiones en AI biopharma provino de grandes acuerdos que superaron los $100 millones.
El informe resalta varias tendencias clave: las rondas de seed representaron el 40% de todos los acuerdos, con el 35% de las empresas que recibieron financiación seed utilizando AI. Las valoraciones mostraron un aumento mediano de 1.5x para las empresas que recaudaron después de rondas de descenso. Mientras que healthtech se enfoca en empresas consolidadas, el sector de diagnóstico/herramientas muestra promesa en biopsias líquidas y diagnósticos de precisión, y el sector de dispositivos ve potencial para un renacimiento a través de innovaciones centradas en hospitales.
실리콘밸리 은행의 최신 건강 관리 투자 및 출구 보고서에 따르면, 2024년 건강 관리 분야의 벤처 캐피탈 투자는 230억 달러에 이르렀고, 2023년의 200억 달러에서 증가했습니다. 인공지능은 특히 바이오 제약 분야에서 30%의 시장 점유율을 차지하며 지배적인 힘으로 부상했습니다.
바이오 제약 AI 분야는 놀라운 성장을 경험하며, 2024년에는 56억 달러를 초과하는 투자가 이루어져, 2023년 대비 300% 증가하고 2021년 수치를 거의 20억 달러 초과했습니다. 주목할 점은 바이오 제약 AI 투자 중 71%가 1억 달러를 초과하는 대형 거래에서 나왔다는 것입니다.
보고서는 몇 가지 주요 트렌드를 강조합니다: 시드 라운드는 모든 거래의 40%를 차지하며, 시드 자금을 받은 회사 중 35%는 AI를 활용하고 있습니다. 평가 결과, 하향 라운드 이후 자금을 조달한 기업의 중간 평가가 1.5배 증가했습니다. 헬스테크가 입증된 기업에 집중하는 반면, 진단/도구 분야는 액체 생검과 정밀 진단에서 가능성이 보이며, 장치 분야는 병원 중심 혁신을 통해 잠재적인 부활을 보고 있습니다.
Le Rapport sur les Investissements et Sorties en Santé du Silicon Valley Bank révèle que l'investissement en capital-risque dans le secteur de la santé a atteint 23 milliards de dollars en 2024, en hausse par rapport à 20 milliards de dollars en 2023. L'Intelligence Artificielle s'est imposée comme une force dominante, en particulier dans le domaine de la biopharma, capturant 30 % de l'investissement total dans la santé.
Le secteur de l'IA biopharma a connu une croissance remarquable, avec des investissements dépassant 5,6 milliards de dollars en 2024, marquant une augmentation de 300 % par rapport à 2023 et dépassant les chiffres de 2021 de près de 2 milliards de dollars. Notamment, 71 % des investissements en IA biopharma provenaient de méga-deals dépassant 100 millions de dollars.
Le rapport met en lumière plusieurs tendances clés : les rondes de seed ont représenté 40 % de tous les accords, avec 35 % des entreprises recevant un financement seed utilisant l'IA. Les évaluations ont montré une augmentation médiane de 1,5x pour les entreprises levant des fonds après des rondes de baisse. Alors que le secteur healthtech se concentre sur des entreprises éprouvées, le secteur des diagnostics/ outils montre des promesses dans les biopsies liquides et le diagnostic de précision, et le secteur des dispositifs voit un potentiel de renaissance grâce à des innovations axées sur les hôpitaux.
Der Bericht über Gesundheitsinvestitionen und -ausstiege von Silicon Valley Bank zeigt, dass das Risikokapitalinvestment im Gesundheitswesen im Jahr 2024 23 Milliarden Dollar erreichte, ein Anstieg von 20 Milliarden Dollar im Jahr 2023. Künstliche Intelligenz trat als dominante Kraft hervor, insbesondere im Bereich der Biopharma, und sicherte sich 30% der Gesamtinvestition im Gesundheitswesen.
Der Sektor der KI in der Biopharma erlebte ein bemerkenswertes Wachstum, mit Investitionen von über 5,6 Milliarden Dollar im Jahr 2024, was einem Anstieg von 300% im Vergleich zu 2023 entspricht und die Zahlen von 2021 um fast 2 Milliarden Dollar übertrifft. Bemerkenswert ist, dass 71% der Investitionen in KI in der Biopharma aus Mega-Deals stammten, die 100 Millionen Dollar überstiegen.
Der Bericht hebt mehrere wichtige Trends hervor: Seed-Runden machten 40% aller Deals aus, wobei 35% der Unternehmen, die Seed-Finanzierung erhielten, KI nutzten. Die Bewertungen zeigten einen medianen Anstieg von 1,5-fach für Unternehmen, die nach Abwärtsrunden Kapital aufnahmen. Während sich Healthtech auf etablierte Unternehmen konzentriert, zeigt der Bereich Diagnostik/Instrumente vielversprechende Ansätze bei flüssigen Biopsien und präzisen Diagnosen, und der Gerätesektor wird durch krankenhausorientierte Innovationen ein potenzielles Wiederaufleben erleben.
- Healthcare VC investment increased 15% YoY to $23 billion in 2024
- Biopharma AI investment surged 300% to $5.6 billion in 2024
- Seed round valuations increased 1.5x median after down rounds
- AI adoption in seed-funded companies increased from 25% to 35% YoY
- IPO activity expected to remain subdued in 2025
- Device startup space experiencing slowdown
- New healthtech startups face pressure to prove themselves quickly
Insights
The $23 billion healthcare VC investment in 2024, up from
The increase in seed rounds to
The substantial investment in biopharma AI marks a critical inflection point where computational drug discovery is transitioning from experimental to mainstream. The focus on liquid biopsies and precision diagnostics in the Dx/Tools sector indicates a strategic alignment with personalized medicine trends. This convergence of AI, diagnostics and therapeutic development creates a powerful feedback loop for accelerated drug development.
The shift in device sector focus toward acute care and hospital settings, moving away from consumer wearables, reflects a pragmatic approach to monetization and clinical validation. This reorientation toward institutional customers could provide more stable revenue streams and clearer regulatory pathways.
The subdued IPO outlook for 2025 despite increased VC activity suggests a maturing market where investors prioritize sustainable growth over quick exits. The concentration of capital in mega-deals indicates a flight to quality, with investors backing established players with proven AI capabilities. This could create a challenging environment for smaller, earlier-stage companies without significant AI components.
The increased focus on seed investments (
New report finds
With more than
"In 2025, we could see a steady yet modest increase in both the volume and value of investments across various healthcare sectors," said Jackie Spencer, Head of Relationship Management for Life Science and Healthcare Banking at Silicon Valley Bank and author of the annual Healthcare Investments and Exits Report. "However, despite this growth, IPO activity is likely to remain subdued as market conditions continue to stabilize and investors remain cautious. Advancements in AI are poised to revolutionize drug development and clinical trial management, driving efficiencies, precision, and speed in bringing new therapies to market."
SVB's 2025 Healthcare Investment and Exits report analyzes and predicts trends for venture capital investing, fundraising, and exits across healthtech, biopharma, diagnostics/tools (dx/tools), and device sectors in the US.
Key report findings:
- Seed Rounds: Seed rounds rose to
40% of all deals as investors look forward. Among all companies receiving a seed deal in 2024,35% are leveraging AI – up from25% in 2023. - Biopharma: With AI-driven protein design gaining momentum and results from clinical trials for AI-designed drugs on the way, excitement for biopharma AI is expected to remain high.
- Valuations: Valuations saw a 1.5x median increase among companies raising after a down round.
- Healthtech: With notable raises going to companies with proven track records and strong histories, a new crop of healthtech startups must prove themselves quickly.
- Dx/Tools: Investments are slowly rising. Liquid biopsies and precision diagnostics companies are showing strength, combining their close relationship to the success of precision therapy with a relatively untapped potential to collect and aggregate data.
- Device: Hospitals might turn out to be the key to reviving a slow device startup space, with new IPOs largely focused on the acute care space. Advances in imaging and monitoring tech are restoring interest that's been lost from wearables and home care.
Learn More
Access SVB's 2025 Healthcare Investments and Exits report here: Healthcare Investments and Exits Report | Silicon Valley Bank
To share its deep industry knowledge, SVB develops various insights reports focused on sectors spanning the innovation economy. For the complete library of SVB's signature research reports, please visit Market Research Industry Trends & Insights | Silicon Valley Bank (svb.com)
About Silicon Valley Bank
Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world's most innovative companies and investors. SVB provides commercial and private banking to individuals and companies in the technology, life science and healthcare, private equity, venture capital and premium wine industries. SVB operates in centers of innovation throughout
View original content to download multimedia:https://www.prnewswire.com/news-releases/venture-capital-fundraising-in-healthcare-remains-healthy-silicon-valley-bank-releases-15th-edition-of-healthcare-investments-and-exits-report-302345432.html
SOURCE Silicon Valley Bank
FAQ
How much was invested in healthcare VC funding in 2024?
What percentage of healthcare investment went to AI companies in 2024?
How much did biopharma AI investment grow in 2024?
What percentage of seed-funded companies used AI in 2024?
What was the median valuation increase for companies raising after down rounds?
What percentage of biopharma AI investment came from mega deals in 2024?
